Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer.
van der Zee AG, Colombo N, Gitsch G, Reed N, Amant F, Cibula D, Kesic VI, Kimmig R, Lopes AD, Markowska J, Marth C, Radolakis A, Salvesen H, Vaitkiene D, Verheijen RH, Zola P. van der Zee AG, et al. Among authors: markowska j. Int J Gynecol Cancer. 2012 Jan;22(1):175. doi: 10.1097/IGC.0b013e3182261f15. Int J Gynecol Cancer. 2012. PMID: 22193647 No abstract available.
Training in bowel and upper abdominal surgery in gynaecological oncology: European Society of Gynecological Oncology (ESGO) Statement.
Cibula D, Verheijen R, Lopes A, Amant F, Beller U, Colombo N, Gitsch G, Kesic V, Kimmig R, Markowska J, Marth C, Reed N, Rodolakis A, Salvesen H, Vaitkiene D, van der Zee AG, Zola P. Cibula D, et al. Among authors: markowska j. Int J Gynecol Cancer. 2011 Oct;21(7):1264-5. doi: 10.1097/IGC.0b013e3182208141. Int J Gynecol Cancer. 2011. PMID: 21720255 No abstract available.
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, Minar L, Melichar B, Hein A, Kieszko D, Pluta M, Spacek J, Bartos P, Wimberger P, Madry R, Markowska J, Streb J, Valha P, Hassan HIB, Pecen L, Galluzzi L, Fucikova J, Hrnciarova T, Hraska M, Bartunkova J, Spisek R. Cibula D, et al. Among authors: markowska j. Gynecol Oncol. 2021 Sep;162(3):652-660. doi: 10.1016/j.ygyno.2021.07.003. Epub 2021 Jul 20. Gynecol Oncol. 2021. PMID: 34294416 Free article. Clinical Trial.
Serum levels of CA 125 and TPS during treatment of ovarian cancer.
Van Dalen A, Favier J, Baumgartner L, Hasholzner U, De Bruijn H, Dobbler D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R. Van Dalen A, et al. Among authors: markowska j. Anticancer Res. 2000 Nov-Dec;20(6D):5107-8. Anticancer Res. 2000. PMID: 11326677
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, Fink D, Ferrero A, McGing P, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R, Goike H. van Dalen A, et al. Among authors: markowska j. Eur J Gynaecol Oncol. 2009;30(6):609-15. Eur J Gynaecol Oncol. 2009. PMID: 20099488
ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016-2019).
Pavlidis N, Madry R, Peeters M, Sandrucci S, Markowska J, Peccatori F, Costa A, Eriksen JG, Ricardi U, Poetter R, Schrijvers D, Vermorken JB; in addition to a list of contributors. Pavlidis N, et al. Among authors: markowska j. J Cancer Educ. 2022 Aug;37(4):1239-1244. doi: 10.1007/s13187-020-01947-3. Epub 2021 Jan 2. J Cancer Educ. 2022. PMID: 33387267
155 results